Failure to submit biological deviation reports.
Inspection Record
Octapharma Dessau GmbH — FDA 483 Findings
Inspectors Lewis K Antwi · Travis S BradleyThe inspectors who signed the published document.Inspector lookup
View the regulator's official source The source document is always the basis for judgement.
Findings
Written records of investigations into unexplained discrepancies do not include the conclusions and follow-up.
The quality control unit lacks responsibility to approve and reject all procedures or specifications impacting on the quality of drug products.
The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in manufacturing and packing.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Diagast2024-04-19 · US FDASimilar to finding 1 Failure to submit a biological deviation report.
- Eugia Steriles Private Limited2026-06-19 · US FDASimilar to finding 2 Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
- Dendreon Pharmaceuticals LLC2026-03-25 · US FDASimilar to finding 4 The batch production and control records are deficient in that they do not include documentation of the accomplishment of each significant step in processing…
- Toyobo Co.2021-02-21 · US FDASimilar to finding 2 Written records of investigations into unexplained discrepancies do not include the conclusions and follow-up.
- Bausch & Lomb, Inc.2016-09-02 · US FDASimilar to finding 2 Written records of investigations into unexplained discrepancies do not include the conclusions and follow-up.
A record as of the US FDA document published on 2026-10-26. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.